

PCL Department Publications - 1999

"A,B"

Khayyam N, Thavendiranathan D, Carmichael FJ, Kus B, Jay V, **Burnham WM**: Neuroprotective effects of acetylsalicylic acid in an animal model of focal brain ischemia. *NeuroReport* 10: 371-374 (1999).

Edwards HE, **Burnham WM**, MacLusky NJ: Testosterone and its metabolites affect afterdischarge thresholds and the development of amygdala kindled seizures. *Brain Res.* 838: 136-150 (1999).

Edwards HE, **Burnham WM**, Mendonca A, Bowlby DA, MacLusky NJ: Steroid hormones affect limbic afterdischarge thresholds and kindling rates in adult female rats. *Brain Res.* 838: 151-157 (1999).

Edwards HE, **Burnham WM**, MacLusky NJ: Focal and generalized seizures differentially affect reproductive function in the male rat. *Epilepsia* 40: 1490-1498 (1999).

Edwards HE, **Burnham WM**, Ng MM, MacLusky NJ: Limbic seizures alter reproductive function in the female rat. *Epilepsia* 40: 1370-1377 (1999).

Bernstein GM, Mendonca A, Wadia J, **Burnham WM**, Jones OT: Kindling induces an asymmetric enhancement of N-type calcium channel density in the dendritic fields of the rat hippocampus. *Neurosci Letts.* 268: 155-158 (1999).

Gombos Z, Spiller A, Cottrell GA, Racine RJ, **Burnham WM**: Mossy fiber sprouting induced by repeated electroconvulsive shock seizures. *Brain Res.* 844: 28-33 (1999).

Bernstein GM, Mendonca A, Wadia J, **Burnham WM**, Jones OT: Kindling induces a long-term enhancement in the density of N-type calcium channels in the rat hippocampus. *Neuroscience* 94: 1083-1095 (1999).

Gombos Z, Mendonca A, Cottrell GA, **Burnham WM**: Ketamine and phenobarbital do not reduce the evoked-potential enhancement induced by electroconvulsive shock seizures in the rat. *Neurosci Letts.* 273: 1-4 (1999).

"C, D"

Lourenco CV, **DaSilva JN**, Wilson AA, Warsh JJ, Houle S: Imaging of cAMP-specific phosphodiesterase-IV: comparison of [11C]rolipram and [11C]Ro 20-1724 in rats. *Synapse* 31: 41-50 (1999).

Lourenco CM, **DaSilva JN**, Wilson AA, Houle S: Metabolism of the phosphodiesterase-4 inhibitor R- [11C]rolipram in rat plasma and brain. *J Label Compd Radiopharm* 42: 663-665 (1999).

DaSilva JN, Schwartz RA, Greenwald ER, Lourenco CM, Wilson AA, Houle S: Dopamine D1 agonist R-[11C]SKF 82957: synthesis and in vivo characterization in rats. *Nucl Med Biol* 26: 537-542 (1999).

Lewis R, Kapur S, Jones C, **DaSilva JN**, Brown G, Wilson A, Houle S, Zipurski R: 5-HT₂ receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-free patients and normal controls. *Am J Psychiatry* 156: 72-78 (1999).

Meyer JH, Kapur S, Houle S, **DaSilva JN**, Owczarek B, Brown G, Wilson AA, Kennedy S: Prefrontal cortex 5-HT₂ receptors in depression: [18F]setoperone PET imaging. *Am J Psychiatry* 156: 1029-1034 (1999).

Wilson AA, Li J, Garcia A, **DaSilva JN**, Houle S: Problems associated with measuring the lipophilicity of radiotracers. *J Label Compd Radiopharm*. 42: 861-863 (1999).

Wilson AA, Li J, Garcia A, **DaSilva JN**, Houle S: Radiosynthesis and biodistribution studies of carbon-11 labelled CCKB antagonists in rats. *J Label Compd Radiopharm*. 42:864-866 (1999).

Wilson AA, Garcia A, Li J, **DaSilva JN**, Houle S: Analogs of WAY 100635 as radiotracers for in vivo imaging of 5-HT_{1A} receptors. *J Label Compd Radiopharm*. 42: 611-620 (1999).

Qi XQ, Newman D, **Dorian P**. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. *J Interv Card Electrophysiol*. 3: 61-67 (1999).

Anderson JL, Hallstrom AP, Epstein AE, Pinski SL, Rosenberg Y, Nora MO, Chilson D, Cannom DS, Moore R, and the AVID Investigators (**P. Dorian** - Investigator). Design and Results of the Antiarrhythmics vs Implantable Defibrillators (AVID) registry. *Circulation* 99: 1692-1699 (1999).

Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, Gent M, Janse MJ, **Dorian P**, Frangin G, and the EMIAT & CAMIAT Investigators. Amiodarone interaction with b-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and

CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. *Circulation* 99: 2268-2275 (1999).

Sloan EP, Natarajan M, Baker B, **Dorian P**, Mironov D, Barr A, Newman DM, Shapiro CM. Nocturnal and daytime panic attacks -- comparison of sleep architecture, heart rate variability and response to sodium lactate challenge. *Biol Psychiatry* 45: 1313-1320 (1999).

Shapiro PA, Lespérance F, Frasura-Smith N, O'Connor CM, Baker B, Jiang JW, **Dorian P**, Harrison W, Glassman AH. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (The "SADHAT" Study). *Am Heart J*. 137: 1100-1106 (1999).

Irvine J, Baker B, Smith J, Jandciu S, Paquette M, Cairns J, Connolly S, Roberts R, Gent M, **Dorian P**. Poor adherence to placebo or amiodarone therapy predicts mortality: Results from the CAMIAT study. *Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med.* 61: 566-575 (1999).

Lee SD, **Dorian P**, Geist M, Davies E, Barr A, Dunne C, Paquette M, Newman D. Validation of a non-invasive measure of local myocardial repolarization in a conscious human model: The adaptation of repolarization to changes in rate. *J Cardiovasc Electrophysiol.* 10: 1171-1179 (1999).

Qi QX, **Dorian P**. Antiarrhythmic drugs and ventricular defibrillation energy requirements. *Chin Med J.* 112: 1147-1152 (1999).

Irvine J, Basinski A, Baker B, Jandciu S, Paquette M, Cairns J, Connolly J, Roberts R, Gent M, **Dorian P**. Depression and risk of sudden cardiac death after acute myocardial infarction: Testing for the confounding effects of fatigue. *Psychosom Med.* 61: 729-737 (1999).

Qi XQ, Newman D, **Dorian P**. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs. *J Cardiovasc Pharmacol.* 34: 898-903 (1999).

"E, F"

Endrenyi L, Tothfalusi L: Subject-by-formulation interaction in determinations of individual bioequivalence: bias and prevalence. *Pharm Res.* 16: 186-190 (1999).

Kalow W, **Endrenyi L**, Tang BK: Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. *Pharmacology* 58: 281-284 (1999).

Kalow W, Ozdemir V, Tang BK, Tothfalusi L, **Endrenyi L**: The science of pharmacological variability: An essay. *Clin Pharmacol Ther.* 66: 445-447 (1999).

"G"

Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HHQ, **George SR**, O'Dowd BF: Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PGPR53 and GPR55: GPR55 is extensively expressed in human brain. *Brain Res Mol Brain Res.* 64: 193-198 (1999).

Lee DK, Nguyen T, O'Neill GP, Cheng R, Liu Y, Howard AD, Coulombe N, Tan CP, Tang-Nguyen A, **George SR**, O'Dowd BF: Discovery of a receptor related to the galanin receptors. *FEBS Letters* 446: 103-107 (1999).

Jin H, **George SR**, O'Dowd BF: Palmitoylation of G protein-coupled receptors. In: D. Sibley and C. Strader, eds. New York: Wiley-Liss Inc., pp. 93-117 (1999).

Marchese A, Nguyen T, Kolakowski LF, Lynch KR, Cheng R, Heng HHQ, **George SR**, O'Dowd BF: Molecular cloning of three novel G protein-coupled receptor genes abundantly expressed in the CNS. *Genomics* 56: 12-21 (1999).

El-Ghundi M, Fletcher P, Drago J, Westphal H, O'Dowd BF, **George SR**: Spatial learning deficit in D1 dopamine receptor knockout mice. *Eur J Pharmacol.* 383: 95-106 (1999).

Lee DK, Nguyen T, Porter CA, Cheng R, **George SR**, O'Dowd BF: Two related G protein-coupled receptors: The distribution of GPR7 in rat brain and the absence of GPR8 in rodents. *Brain Res Mol Brain Res.* 71: 96-103 (1999).

Pak Y, O'Dowd BF, **George SR**: Agonist-induced, G protein-dependent and -independent internalization of the mu opioid receptor. *J Biol Chem.* 274: 27610-27616 (1999).

Xie Z, Lee SP, O'Dowd BF, **George SR**: Serotonin 5HT1B and 5HT1D receptors form homodimers when expressed alone and heterodimers when coexpressed. *FEBS Letters* 456: 193-198 (1999).

Marchese A, **George SR**, Kolakowski LF, Lynch KR, O'Dowd BF: Novel G protein coupled receptors and their endogenous ligands: Expanding the boundaries of physiology and pharmacology. *TIPS Reviews* 20: 370-375 (1999).

Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, **George SR**, Evans JF, Caskey CT: Identification of Urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. *Biochem Biophys Res Commun* 266: 174-178 (1999).

Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D, **Goldenberg GJ**: P53 Gene Status and Chemosensitivity of Childhood Acute Lymphoblastic Leukemia Cells to Adriamycin. *Leukemia Res.* 23: 871-880 (1999).

Grant DM: Pharmacogenomics and the changing face of clinical pharmacology. *Can J Clin Pharmacol.* 6: 131-132 (1999).

"H"

Moore PA, Gage TW, Hersh EV, Yagiela JA, **Haas DA:** Adverse drug interactions in dental practice: professional and educational implications. *J Amer Dental Assoc.* 130: 47-54 (1999).

Haas DA: Adverse drug interactions associated with analgesics. *J Amer Dental Assoc.* 130: 397-407 (1999).

Thomsen C, **Hampson DR:** Contribution of metabotropic glutamate. mGluR4 to [3H]L-2-amino-4-phosphonobutyrate binding in mouse brain. *J Neurochem.* 72: 835-840 (1999).

Han G, **Hampson DR:** Ligand binding to the amino terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. *J Biol Chem.* 274: 10008-10013 (1999).

Elezgarai I, Benitez R, Mateos JM, Lázaro E, Osorio A, Azkue JJ, Bilbao A., Lingenhoehl K, Van der Putten H, **Hampson DR,** Kuhn R, Knöpfel T, Grandes P: Developmental expression of the group III metabotropic glutamate receptor mGluR4a in the medial nucleus of the trapezoid body of the rat. *J Comp Neurol.* 411: 431-440 (1999).

Hampson DR, Huang XP, Pekhletski R, Peltekova V, Hornby G, Thomsen C, Thogersen H: Probing the ligand binding domain of the mGluR4 subtype of metabotropic glutamate receptor. *J Biol Chem.* 274: 33488-33495 (1999).

"I, J"

Jorge LF, Eichelbaum M, Griese EU, **Inaba T,** Arias TD: Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Columbia: role of selection versus drift in world populations. *Pharmacogenetics* 9:217-228 (1999).

Sumida A, Kinoshita K, Fukuda T, Matsuda H, Yamamoto I, **Inaba T,** Azuma J: Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. *Biochem Biophys Res Comm.* 262: 499-503 (1999).

Fujimaki Y, Arai N, Hokusui H, **Inaba T:** Identification of human liver cytochromes P450 involved in metabolism of ecabapide, a prokinetic agent. *Xenobiotica* 29:1273-1282 (1999).

Ito S, Woodland C, Sarkadi B, Hockman G, Walker S, Koren G: Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. *Am J Physiol.* 277: F84-F96 (1999).

Ito S: Drug secretion systems in renal tubular cells: functional models and molecular identity. *Ped Nephrol.* 13: 980-8 (1999).

Stiska J, **Ito S**, Dunn M, Shennan A, O'Brien K, Kelly E, Koppel R, Cox DW, Rabinovitch M: Functional and analgesic concentrations of alpha 1-proteinase inhibitor after administration for the prevention of chronic lung disease of prematurity. *Biol Neonat.* 76: 134-43 (1999).

Ito S, Lieu M, Chan W, Koren G: Maternal drug therapy as a risk factor for shorter duration of breastfeeding. *Ped Perinatal Drug Ther.* 3: 44-48 (1999).

Koren G, Moretti M, **Ito S**: Continuing drug therapy while breastfeeding. *Can Fam Phys.* 45: 897-899 (1999).

Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, **Ito S**, Koren G: Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. *J Clin Pharmacol.* 39: 1-8 (1999).

"K"

Kalant H: Differentiating drugs by harm potential: the rational versus the feasible. *Substance Use & Misuse* 34: 25-34 (1999).

Kalant H: Addiction. In: G. Adelman and B. H. Smith, eds. *Encyclopedia of Neuroscience*, 2nd ed. Amsterdam: Elsevier Science, pp. 19-21, (1999).

Lanqa AJ, Wu PH, Jung B, Litt J-F, Ng V, **Kalant H**: Differential increase of Fos immunoreactivity in hypothalamic and septal nuclei by arginine⁸-vasopressin and desglycinamide⁹-arginine¹⁸- vasopressin. *Neuroscience* 91: 1331-1341 (1999).

Kalant H, Poikolainen K: Moderate drinking: concepts, definitions, and public health significance. In 1. Macdonald (ed.): *Health Issues Related to Alcohol Consumption*, 2nd edition, ILSI Europe, Brussels, and Blackwell Science, Oxford, pp. 1-25, (1999).

Kalant H: Obituary - Jorge Mardones (1908-1998). *Addiction* 94: 1755-1757 (1999).

Kalant H, Corrigan WA, Hall W, Smart RG (eds): *The Health Effects of Cannabis*, xiii + 526 pp. Toronto. ARF Books (1999)

Özdemir V, Tyndale RF, Reed K, Herrmann N, Sellers EM, **Kalow W**, Naranjo C: Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. *J Clin Psychopharmacol.* 19: 472-475 (1999).

Kalow W: Pharmacogenetic research: A revolutionary science. (Editorial). *J Psychiatry Neurosci.* 24: 139-140 (1999).

Kalow W, Endrenyi L, Tang BK: Repeat administration of drugs as a means to assess the genetic component in pharmacological variability: A commentary. *Pharmacology* 58: 281-284 (1999).

Kalow W, Özdemir V, Tang BK, Tothfalusi L, Endrenyi L: The science of pharmacological variability: An essay. *Clin Pharmacol Ther.* 66: 445-447 (1999).

Özdemir V, Masellis M, Basile VS, **Kalow W**, Meltzer HY, Liberman JA, Kennedy JL: Variability in response to clozapine: Potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene. *CNS Spectrums* 4: 30-34, 47-52 (1999).

Khanna JM, Morata GS, Ferreira VMM. NMDA Antagonists and Tolerance to Drugs Affecting the Central Nervous System. *CNS Drug Rev.* 5: 165-176 (1999).

Furukawa Y, Nygaard TG, Gutlich M, Rajput AH, Pifl C, DiStefano L, Chang LJ, Price K, Shimadzu M, Hornykiewicz O, Haycock JW, **Kish SJ**: Striatal bipterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. *Neurology* 53: 1032-1041 (1999).

Furukawa Y, **Kish SJ**: Dopa-responsive dystonia: recent advances and remaining issues to be addressed. *Movement Disorders* 14: 709-715 (1999).

Fields A, Li PP, **Kish SJ**, Warsh JJ: Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. *J Neurochem.* 73:1704-1710 (1999).

Fallbrook A, Turenne SD, Mamalias N, **Kish SJ**, Ross BM: Phosphatidylcholine and phosphatidylethanolamine metabolites may regulate brain phospholipid catabolism via inhibition of lysophospholipase activity. *Brain Res.* 834: 207-210 (1999).

Kish SJ, Kalasinsky KS, Furukawa Y, Guttman M, Ang L, Li L, Adams V, Reiber G, Anthony RA, Anderson W, Smialek J, DiStefano L: Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin. *Mol Psychiatry* 4: 26-32 (1999).

Ross BM, Turenne S, Moszczynska A, Warsh JJ, **Kish SJ**: Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. *Brain Res.* 821: 407-413 (1999).

Kish SJ, Mastrogiacomo F, Guttman M, Furukawa Y, Taanman JW, Dozic S, Pandolfo M, Lamarche J, DiStefano L, Chang LJ: Decreased brain protein levels of cytochrome oxidase subunits in Alzheimer's disease and in hereditary spinocerebellar ataxia disorders: a nonspecific change? *J Neurochem* 72: 700-707 (1999).

Bishai R, Arbour L, Lyons C, **Koren G**: Intrauterine exposure to clomiphene and neonatal persistent hyperplastic primary vitreous. *Teratology* 60: 143-5 (1999).

McMartin KI, **Koren G**: Proactive approach for the evaluation of fetal safety in chemical industries. *Teratology* 60: 130-6 (1999).

Koren G: Risks for FAS. *Teratology* 60: 112 (1999).

Hackman R, Kapur B, **Koren G**: Use of the nicotine patch by pregnant women. *New Engl J Med.* 341: 1700 (1999).

Bar-Oz B, Moretti ME, Mareels G, Van Tittelboom T, **Koren G**: Reporting bias in retrospective ascertainment of drug-induced embryopathy. *Lancet* 354: 1700-1 (1999).

Loebstein R, Lalkin A, Addis A, Costa A, Lalkin I, Bonati M, **Koren G**: Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. *J Allergy Clin Immunol.* 104: 953-6 (1999).

Emelianova S, Mazzotta P, Einarson A, **Koren G**: Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. *Clin Investigative Med.* 22: 106-10 (1999).

Einarson A, **Koren G**: Dextromethorphan. Extrapolation of findings from reproductive studies in animals to humans. *Can Fam Phys.* 45: 2309-10 (1999).

Koren G: The association between maternal cigarette smoking and psychiatric diseases or criminal outcome in the offspring: a precautionary note about the assumption of causation. *Reprod Toxicol.* 13: 345-6 (1999).

Pastuszak A, Bhatia D, Okotore B, **Koren G**: Preconception counseling and women's compliance with folic acid supplementation. *Can Fam Phys.* 45: 053-7 (1999).

Mazzotta P, Magee LA, Maltepe C, Lifshitz A, Navioz Y, **Koren G**: The perception of teratogenic risk by women with nausea and vomiting of pregnancy. *Reprod Toxicol.* 13: 313-9 (1999).

Nulman I, Laslo D, **Koren G**: Treatment of epilepsy in pregnancy. *Drugs* 57: 870 (1999).

Diav-Citrin O, Okotore B, Lucarelli K, **Koren G**: Pregnancy outcome following first-trimester exposure to zopiclone: a prospective controlled cohort study. *Am J Perinatology* 16: 157-60 (1999).

Pastrakuljic A, Derewlany LO, **Koren G**: Maternal cocaine use and cigarette smoking in pregnancy in relation to amino acid transport and fetal growth. *Placenta* 20: 499-512 (1999).

Stevens B, Johnston C, Taddio A, Jack A, Narciso J, Stremmler R, **Koren G**, Aranda J: Management of pain from heel lance with lidocaine-prilocaine (EMLA) cream: is it safe and efficacious in preterm infants? *J Developm Behav Pediatrics* 20: 216-21 (1999).

Bishai R, Taddio A, Bar-Oz B, Freedman MH, **Koren G**: Relative efficacy of amethocaine gel and lidocaine-prilocaine cream for Port-a-Cath puncture in children. *Pediatrics* 104: e31 (1999).

Bar-Oz B, Ford-Jones L, **Koren G**: Congenital rubella syndrome. How can we do better? *Can Fam Phys.* 45: 1865-9 (1999).

Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, **Koren G**: Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. *Am J Physiol.* 277: F84-96 (1999).

Koren G, Kennedy D: Safe use of valproic acid during pregnancy. *Can Fam Phys.* 45: 1451-3 (1999).

Magee LA, Nulman I, Rovet JF, **Koren G**: Neurodevelopment after in utero amiodarone exposure. *Neurotoxicol Teratol.* 21: 261-5 (1999).

McMartin KI, **Koren G**: Exposure to organic solvents. Does it adversely affect pregnancy? *Can Fam Phys.* 45: 1671-3 (1999).

Berkovitch M, Eshel G, Lushkov G, Reznik S, Chen-Levy Z, Pinto O, **Koren G**: The effect of diazepam in the recovery of rabbits from acute acetaminophen intoxication. *Therap Drug Monit.* 21: 267-73 (1999).

Atanackovic G, **Koren G**: Young women taking isotretinoin still conceive. Role of physicians in preventing disaster. *Can Fam Phys.* 45: 289-92 (1999).

Klein J, **Koren G**: Hair analysis--a biological marker for passive smoking in pregnancy and childhood. *Human Exper Toxicol.* 18: 279-82 (1999).

Kapur B, Hershkop S, **Koren G**, Gaughan V: Urine fingerprinting: detection of sample tampering in an opiate dependency program. *Therap Drug Monit.* 21: 243-50 (1999).

Addis A, Loebstein R, **Koren G**, Einarson TR: Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). *Eur J Clin Pharmacol.* 55: 1-6 (1999).

Schuler L, Pastuszak A, Sanseverino TV, Orioli IM, Brunoni D, Ashton-Prolla P, Silva da Costa F, Giugliani R, Couto AM, Brandao SB, **Koren G**: Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. *Reprod Toxicol.* 13: 147-51 (1999).

Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, **Koren G**: Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.

J Clin Pharmacol. 39: 454-61 (1999).

Koren G, Moretti M, Ito S: Continuing drug therapy while breastfeeding. Part 2. Common misconceptions of physicians. Can Fam Phys. 45: 1173-5 (1999).

Mazzotta P, Loebstein R, **Koren G**: Treating allergic rhinitis in pregnancy. Safety considerations. Drug Safety 20: 361-75 (1999).

Bishai R, **Koren G**: Maternal and obstetric effects of prenatal drug exposure. Clinics in Perinatology 26: 75-86 (1999).

Diav-Citrin O, Atanackovic G, **Koren G**: An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. Therap Drug Monit. 21: 74-81 (1999).

Lalkin A, Kapur BM, **Koren G**: Contamination of antibiotics resulting in severe pediatric methadone poisoning. Annals Pharmacother. 33: 314-7 (1999).

Mathur R, Zhou J, Babila T, **Koren G**: Ile-177 and Ser-180 in the S1 segment are critically important in Kv1.1 channel function. J Biol Chem. 274: 11487-93 (1999).

Valverde P, Koren G: Purification and preliminary characterization of a cardiac Kv1.5 repressor element binding factor. Circul Res. 84: 937-44 (1999).

Ito S, Lieu M, Chan W, **Koren G**: Continuing drug therapy while breastfeeding. Part 1. Common misconceptions of patients. Can Fam Phys. 45: 897-9 (1999).

Mankuta D, Bar-Oz B, **Koren G**: Erythema infectiosum (Fifth disease) and pregnancy. Can Fam Phys. 45: 603-5 (1999).

Khattak S, K-Moghtader G, McMartin K, Barrera M, Kennedy D, **Koren G**: Pregnancy outcome following gestational exposure to organic solvents: a prospective controlled study. JAMA 281: 1106-9 (1999).

Einarson A, Bailey B, **Koren G**: Pregnancy outcome of women exposed to pinaverium due to a dispensing error. Annals Pharmacother. 33: 112-3 (1999).

Diav-Citrin O, Hunnisett L, Sher GD, **Koren G**: Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. Am J Hematol. 60: 148-50 (1999).

"L"

Lança AJ: Functional organization of the central nervous system. In: Principles of Medical Pharmacology. Oxford University Press, pp. 217-240 (1998).

Lança AJ, Wu PW, Jung B, Liu J-F, Ng V, Kalant H: Differential increase in Fos immunoreactivity in hypothalamic and septal nuclei by arginine-8-vasopressin and desglycinamide-9-arginine-8-vasopressin. *Neuroscience* 91: 1331-1341 (1999).

Le AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y.: Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. *Neuropsychopharmacology*. 21: 435-444 (1999).

Buczek Y, Le AD, Stewart J, Shaham Y.: Stress reinstates nicotine seeking but not sucrose solution seeking in rats. *Psychopharmacology*. 144: 183-188 (1999).

Andreopoulos S, Li PP, Siu KP, Warsh JJ: Characterization of ADP-ribosylated substrate proteins in postmortem human brain. *J Neurosci Res*. 56: 632-643 (1999).

Fields A, Li PP, Kish SJ, Warsh, JJ: Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. *J Neurochem*. 73: 1704-1710 (1999).

Reiach JS, Li PP, Warsh JJ, Kish SJ, Young LT: Reduced adenylyl cyclase immunolabeling, expression and activity in postmortem temporal cortex of depressed suicide subjects. *J Affective Disorder* 56: 141-151 (1999).

"M"

Sattler R, Xiong Z, Lu W-Y, MacDonald JF, Tymianski M: Distinct Roles of Synaptic and Extrasynaptic NMDA Receptors in Excitotoxicity. *J Neurosci*. 20: (2000).

Bai D, Pennefather PS, MacDonald JF, Orser BA: The General Anesthetic Propofol Slows Deactivation and Desensitization of GABAA Receptors. *J Neurosci*. 19: (1999).

Lei S, Lu W-Y, Xiong Z-G, Orser BA, Valenzuela CF, MacDonald JF: Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons. *J Biol Chem*. 274: 30617-30623 (1999.).

Joo DT, Xiong Z-G, **MacDonald JF**, Jia Z, Roder J, Sonner J, Orser BA: Blockade of glutamate receptors and barbiturate anesthesia: increased sensitivity to pentobarbital-induced anaesthesia despite reduced inhibition of AMPA receptors in GluR2 null mutant mice. *Anesthesiology* 91:1329-1341 (1999).

Xiong ZG, Lu WY, **MacDonald JF**, Lu YM, Roder JC, Pelkey KA, Salter MW: Src enhancement of native NMDA channel function not via removal of zinc inhibition. *J Neurosci*. 19:1-6 (1999).

Sattler R, Xiong Z, Lu W-Y, Hafner M, **MacDonald JF**, Tymianski M: Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. *Science* 284:1845-8 (1999).

Lu, W-Y, Xiong Z-Y, Lei S, Orser BA, **MacDonald JF**: G-Protein Coupled Receptors Potentiate NMDA Channel Activity Through A Protein Kinase C and Tyrosine kinase (Src) Signalling Cascade. *Nature Neurosci*. 2: 331-8 (1999).

Xiong ZG, **MacDonald JF**: Sensing of Extracellular Calcium by Neurones. In press. *Can J Physiol Pharmacol*. 77: 715-721 (1999).

Crowther Labiris NR, Holbrook AM, Chrystyn H, **MacLeod SM**: Newhouse MT.: Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. *Am J Respi Crit Care Med*. 160: 1711-1716 (1999).

Willison DJ, **MacLeod SM**: The role of research evidence in pharmaceutical policy making: evidence when necessary but not necessarily evidence. *J Eval Clin Practice*. 5:243-249 (1999).

MacLeod SM: Basic science in medical education [editorial]. *Clin Investigative Med* 22:23-24 (1999).

Mittmann N, Herrmann N, Shulman KI, Silver IL, Busto UE, Borden EK, Naranjo CA, Shear NH: The effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study. *J Clin Psychiatry* 60: 690-697 (1999).

Mittmann N, Liu BA, Knowles SR, Shear NH: Meta-analysis and adverse events. *Can Med Assoc Journal* 160: 987 (1999).

Mittmann N, Trakas K, Risebrough N, Liu BA: Utility scores for chronic conditions in a community-dwelling population. *PharmacoEconomics* 15: 369-376 (1999).

"N"

Naranjo CA, Sproule BA, Knoke DM: Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. *Int Clin Psychopharmacol.* 14: S35-S47 (1999).

Mittmann N, Herrmann N, Shulman KI, Silver IL, Busto UE, Borden EK, **Naranjo CA**, Shear NH: The effectiveness of antidepressants in elderly depressed outpatients: A prospective case series study. *J Clin Psychiatry* 60: 690-697 (1999).

Naranjo CA, Busto U, Ozdemir V: Current clinical assessment and management of drug dependence. In: Niesink RJM, Jaspers RMA, Kornet LMW, van Ree JM, eds. *Drugs of Abuse and Addiction: Neurobehavioral Toxicology*. CRC Press and Open University of The Netherlands, pp. 244-272 (1999).

Cameron RG, **Neuman MG**: Alcohol mediated toxicity in human biopsies. *Clin Biochem.* 32: 579-586 (1999)

Neuman MG, Haber J, Katz GG, Malkiewicz IM, Shear NH: Cytochrome P450 2E1 enhances methotrexate-induced hepatocytotoxicity. *Clin Biochem.* 32: 519- 536 (1999).

Neuman MG, Benhamou JP, Shear NH, Martinot M, Boyer N, Katz GG, Sujena A, Seigh S, Marcellin P: Cytokines as a predictors therapy response in chronic hepatitis C- role of monotherapy with Interferon. *Clin Biochem* 32: 537B546 (1999).

Neuman MG: Cytokines and Inflamed Liver Editorial. *Clin Biochem.* 32: 514-517 (1999).

Neuman MG, Cameron RG, Shear NH, Blendis LM: Electron microscopic study on antifibrotic effects of ursodeoxycholate treatment in primary biliary cirrhosis. In: Paumgartner G, Stiehl A, Keppler D, Gerok W, Leuschner U, eds. *Bile Acids in Cholestasis*. Lancaster, UK: Kluwer Academic Publishers, pp264-279 (1999).

Neuman MG, Cameron RG, Fauer G, Shear NH. Drug-induced apoptosis. In: Cameron RG, Fauer G, eds. *Handbook of Experimental Pharmacology: Apoptosis modulation by drugs*. Heidelberg: Springer Verlag Publishers, pp154-64 (1999).

Pessayre D, Feldman G, **Neuman MG**: Endogenous, cytokines and natural substances-induced apoptosis. In: Cameron RG, Fauer G, eds. *Handbook of Experimental Pharmacology: Apoptosis modulation by drugs*. Heidelberg: Springer Verlag Publishers, pp20-54 (1999).

Sugamori KS, Lee FJ, Pristupa ZB, **Niznik HB**: A cognate dopamine transporter-like activity endogenously expressed in a COS-7 kidney-derived cell line. *FEBS Letters* 451: 169-174 (1999).

Wan Q, Man HY, Liu F, Braunton J, **Niznik HB**, Pang SF, Brown GM, Wang YT: Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. *Nature Neuroscience* 2: 401-403 (1999).

Chacur C, Raymond R, Hipólido DC, Giugliano EB, Leite JR, **Nobrega JN**: Immediate increase in benzodiazepine binding in rat brain after a single brief experience in the plus maze: A paradoxical effect. *Neurosci Letts*. 269: 29-32 (1999).

Souza-Formigoni MLO, De Lucca EM, Hipólido DC, Enns SC, Oliveira MGM, **Nobrega JN**: Sensitization to Ethanol's Stimulant Effect is Associated with Region-Specific Increases in Brain D2 Receptor Binding. *Psychopharmacology* 146: 262-267 (1999).

Friedman Y, Bacchus R, Raymond R, Joffe RT, **Nobrega JN**: Acute stress increases thyroid hormone levels in rat brain. *Biol Psychiatry* 45: 234-237 (1999).

Richter A, Ebert U, **Nobrega JN**, Vallbacka J, Fedrowitz M, Loscher W: Immunohistochemical and neurochemical studies on nigral and striatal functions in the circling (ci) rat, a genetic animal model with spontaneous rotational behavior. *Neuroscience* 89: 461-471 (1999).

Nobrega JN, Gernert M, Loscher W, Belej T, Raymond R, Richter A: Tyrosine hydroxylase immunoreactivity and [3H]WIN 35,428 binding to the dopamine transporter in a hamster model of idiopathic paroxysmal dystonia. *Neuroscience* 92: 211-217 (1999).

"O"

Sawzdargo M., Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HHQ, George SR, **O'Dowd BF**: Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PGPR53 and GPR55: GPR55 is extensively expressed in human brain. *Brain Res Mol Brain Res*. 64: 193-198 (1999).

Lee DK, Nguyen T, O'Neill GP, Cheng R, Liu Y, Howard AD, Coulombe N, Tan CP, Tang-Nguyen A, George SR, **O'Dowd BF**: Discovery of a receptor related to the galanin receptors. *FEBS Letters* 446: 103-107 (1999).

Jin H, George SR, **O'Dowd BF**: Palmitoylation of G protein-coupled receptors. In: D. Sibley and C. Strader, New York: Wiley-Liss Inc., pp. 93-117 (1999).

Marchese A, Nguyen T, Kolakowski LF, Lynch KR, Cheng R, Heng HHQ, George SR, **O'Dowd BF**: Molecular cloning of three novel G protein-coupled receptor genes abundantly expressed in the CNS. *Genomics* 56: 12-21 (1999).

El-Ghundi M, Fletcher P, Drago J, Westphal H, **O'Dowd BF**, George SR: Spatial learning deficit in D1 dopamine receptor knockout mice. *Eur J Pharmacol* 383: 95-106 (1999).

Lee DK, Nguyen T, Porter CA, Cheng R, George SR, **O'Dowd BF**: Two related G protein-coupled receptors: The distribution of GPR7 in rat brain and the absence of GPR8 in rodents. *Brain Res Mol Brain Res.* 71: 96-103 (1999).

Pak Y, **O'Dowd BF**, George SR: Agonist-induced, G protein-dependent and -independent internalization of the mu opioid receptor. *J Biol Chem.* 274: 27610-27616 (1999).

Xie Z, Lee SP, **O'Dowd BF**, George SR: Serotonin 5HT1B and 5HT1D receptors form homodimers when expressed alone and heterodimers when coexpressed. *FEBS Letters*, 456: 193-198 (1999).

Marchese A, George SR, Kolakowski LF, Lynch KR, **O'Dowd BF**: Novel G protein coupled receptors and their endogenous ligands: Expanding the boundaries of physiology and pharmacology. *TIPS Reviews* 20: 370-375 (1999).

Jin H, Xie Z, George SR, **O'Dowd BF**: Palmitoylation occurs at cysteine 347 and cysteine 351 of the D1 dopamine receptor. *TIPS* 20: 370-375 (1999).

Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, **O'Dowd BF**, Duckles SP, Civelli O: Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. *Nature Cell Biology* 1: 383-385 (1999).

Leiter LA, Abbott D, Campbell N, Mendelson R, **Ogilvie RI**, Chockalingham A: Lifestyle modification to prevent and control hypertension. 2 Recommendations on obesity and weight loss. *Canad Med Assoc J.* 160: S7-S12 (1999).

Pohjanvirta R, Viluksela M, Tuomisto JT, Unkila M, Karasinska J, Franc MA, Holowenko M, Giannone JV, Harper PA, Tuomisto J, **Okey AB**: Physicochemical differences in the AH receptors of the most TCDD-susceptible and most TCDD-resistant rat strains. *Toxicol Appl Pharmacol.* 155: 82-95 (1999).

"P, Q"

Wang MM, Reynaud D, **Pace-Asciak CR**: In vivo stimulation of 12(S)-lipoxygenase in the rat skin by bradykinin and platelet activating factor - formation of 12(S)-HETE and hepoxilins - actions on vascular permeability. *Biochim Biophys Acta* 1436: 354-362 (1999).

Reynaud D, Demin PM, Sutherland M, Nigam S, **Pace-Asciak CR**: Hepoxilin signaling in intact human neutrophils - biphasic elevation of intracellular calcium by unesterified hepoxilin A3. *FEBS Letters* 446: 236-238 (1999).

Wang MM, Demin PM, **Pace-Asciak CR**: Stereoselective Actions of Hepoxilins A3 and B3 and their Cyclopropane Analogs (Hx A3 & Hx B3) on Bradykinin and PAF-evoked Potentiation of Vascular Permeability in Rat Skin. *Gen Pharm.* 33: 377-382 (1999).

Reynaud D, Ali M, Demin P, **Pace-Asciak CR**: Formation of 14,15-hepoxilins of the A3 and B3 series through a 15-lipoxygenase and hydroperoxide isomerase present in garlic roots. *J Biol Chem.* 274: 28213-28218 (1999).

Demin PL, Vasilyeva LL, Kochev DM, Pivnitsky KK, **Pace-Asciak CR**: Synthesis of tritium labeled 20-hydroxy hepoxilin A3, the major hepoxilin metabolite in human neutrophils. *J Labelled Compd Radiopharm.* 42: 773-779 (1999).

Pace-Asciak CR, Demin PM, Estrada M, Liu G-L: Hepoxilins raise circulating insulin levels in vivo. *FEBS Letters* 461: 165-168 (1999).

Chen P, Policova Z, **Pace-Asciak CR**, Neumann, AW: Study of binding of 12(S)-hydroxy-5(Z), 8(Z), 10(E), 14(Z)-eicosatetraenoic acid to bovine serum albumin using dynamic surface tension measurements. *J Pharmac Sci.* 88: 1293-1298 (1999).

Geng W, **Pang KS**: Differences in excretion of hippurate, as a metabolite of benzoate and as an administered species in the single pass isolated perfused rat kidney explained. *J Pharmacol Exp Ther.* 288: 597-606 (1999).

Tan E, Tirona RG, **Pang KS**: Lack of zonal uptake of estrone sulfate in enriched periportal and perivenous isolated rat hepatocytes. *Drug Metab Dispos.* 27: 336-341 (1999).

Schwab AJ, **Pang KS**: The multiple indicator dilution method for the study of enzyme heterogeneity in liver: Theoretical basis. *Drug Metab Dispos.* 27: 746-755 (1999).

Sirianni GL, **Pang KS**: Inhibition of esterolysis of enalapril by paraoxon increases the urinary clearance in isolated perfused rat kidney. *Drug Metab Dispos.* 27: 931-936 (1999).

Tirona RG, **Pang, KS**: Bimolecular glutathione conjugation of ethacrynic acid and efflux of the glutathione adduct by periportal and perivenous rat hepatocytes. *J Pharmacol Exp Ther.* 290: 1230-1241 (1999).

Tirona, RG, Tan, E, Meier G, **Pang KS**: Uptake and glutathione conjugation kinetics of ethacrynic acid in rat liver: in vitro and perfusion studies. *J Pharmacol Exp Ther.* 291: 1210-1219 (1999).

Silva GA, Theriault E, Mills LR, **Pennefather PS**, Feeney CJ: Group I and II metabotropic glutamate receptor expression in cultured rat spinal cord astrocytes. *Neurosci Letts.* 263: 117-120 (1999).

Prokipcak RD, Raouf A, Lee C: The AU-rich 3' untranslated region of the human MDR1 mRNA is an inefficient mRNA destabilizer. *Biochem. Biophys. Res Comm.* 261: 627-634 (1999).

"R"

Wang K, Ramji S, Bhatena A, Lee C, **Riddick DS**: Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. *Xenobiotica* 29: 155-170 (1999).

Di Re J, Lee C, **Riddick DS**: Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. *Can J Physiol Pharmacol.* 77: 589-597 (1999).

Smalley M, Leiper K, Floyd D, Mobberley M, Ryder T, Selden C, **Roberts EA**, Hodgson H: Behavior of a cell line derived from normal human hepatocytes on non-physiological and physiological-type substrates: evidence for enhancement of secretion of liver-specific proteins by a three-dimensional growth pattern. *In Vitro Cellular & Developmental Biology. Animal* 35: 22-32 (1999).

Roberts EA: Primary sclerosing cholangitis in children. *J Gastroenterol Hepatol.* 14: 588-593 (1999).

Roberts EA: McNair et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis. *Amer J Gastroenterol.* 94: 291-292 (1999).

"S"

Parker KL, Schedl A, **Schimmer BP**: Gene interactions in gonadal development. *Annu Rev Physiol.* 61: 417-433 (1999).

Parker KL, **Schimmer BP**, Schedl A: Genes essential for early events in gonadal development. *Cell Mol Life Sci.* 5: 831-838 (1999).

Seeman P, Tamminga C: Pruning during development. *Am J Psychiat.* 156: 168 (1999).

Seeman P, Tallerico T: Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine. *Amer J Psychiat.* 156: 876-884 (1999).

Fitzgerald P, Kapur S, **Seeman P**: Neuroreceptor studies in psychotic disorders in the elderly: Potential for understanding antipsychotic effects. In: Howard R, Rabins PV, Castle DJ, eds. *Late Onset schizophrenia*. Petersfield, U.K: Wrightson Biomedical Publishing Ltd., pp. 205-214 (1999).

Seeman P, Kapur S: Olanzapine binding to dopamine receptors in vitro and in vivo. In: Tran PV, Herrera J, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G, eds. *Olanzapine (Zyprexa) - A Novel antipsychotic*. Indianapolis: Eli Lilly & Co., (1999).

Seeman P: The dopamine receptor basis of psychosis. In: Breier A, Tran PV, Herrera J, Bymaster F, Tollefson G, eds. *Current issues in the psychopharmacology of schizophrenia*. Indianapolis: Eli Lilly & Co., (1999).

Wadenberg M-L, **Seeman P**: Clozapine pretreatment enhances raclopride catalepsy. *Eur J Pharmacol.* 377: R1-R2 (1999).

Sellers EM, Hoornweg K, Busto UE, Romach MK: Risk of drug dependence and abuse posed by barbiturate-containing analgesics. *Can J Clin Pharmacol.* 6: 18-25 (1999).

Lelas S, Wegert S, Otton SV, **Sellers EM**, France CP: Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. *Drug Alcohol Depend* 54: 239-249 (1999).

Tyndale RF, Li Y, Li N-Y, Messina E, Miksys S, **Sellers EM**: Characterization of CYP2D1 activity in rat brain: High affinity kinetics for dextromethorphan. *Drug Metab Dispos.* 27: 924-930 (1999).

Busto UE, Zawertailo LA, Kaplan HL, **Sellers EM**: Identifying appropriate subjects for abuse liability studies using pre-study pharmacological testing. *Can J Clin Pharmacol.* 6: 103-110 (1999).

Sproule BA, Busto UE, Somer G, Romach MK, **Sellers EM**: Characteristics of dependent and non-dependent regular users of codeine. *J Clin Psychopharmacol.* 19: 367-372 (1999).

Romach MK, Sproule BA, **Sellers EM**, Somer G, Busto UE. Long-term codeine use is associated with depressive symptoms. *J Clin Psychopharmacol.* 19: 373-376 (1999).

Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O'Brien CP, **Sellers EM**: Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). *Arch Gen Psychiatry* 56: 1101-1106 (1999).

Tyndale RF, Pianezza ML, **Sellers EM**: A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. *Nicotine & Tobacco Res.* 1: S63-S67 (1999).

Sellers EM, Romach MK, Tyndale RF: Pharmacogenetic basis of variation in drug dependence. In: Tucker GT, ed. *Excerpta Medica International Congress Series. Volume 1178: Variability in Human Drug Response.* Amsterdam: Elsevier Science B.V., pp. 219-229 (1999).

Semple JW, Speck ER, Cosgrave Lazarus AH, Blanchette V, Freedman J: Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. *Blood* 93: 713-720 (1999)

Mody M, Lazarus AH, **Semple JW**, Freedman J: Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. *Transfusion Med* 9: 147-154 (1999).

Semple JW, Freedman J: The basic immunology of platelet-induced alloimmunization. In: Kicker TS, Herman JH eds. *Current issues in platelet transfusion therapy and platelet alloimmunity.* Bethesda: American Association of Blood Banks, pp 77-101 (1999).

Freedman J, **Semple JW**: Clinical studies of blood transfusion and survival of renal allografts. In: Vamvakas EC, Blaichman MA, eds. *The Immunomodulatory Effects of Blood Transfusion.* Bethesda: American Association of Blood Banks, pp 129-144 (1999).

Walmsley SL, Khorasheh S, Singer J, Djurdjev O, and the Canadian HIV Trials Network 057 Study Group (**Shear NH**): A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in *Pneumocystis carinii* pneumonia prophylaxis (CTN 057). *J AIDS Hum Retrovirol* 19: 498-505 (1999).

Shear NH, Levine C: Needs survey of Canadian rosacea patients. *J Cutan Med Surg.* 3: 178-81 (1999).

Mittmann N, Herrmann N, Shulman KI, Silver IL, Busto UE, Borden EK, Naranjo CA, **Shear NH**: The effectiveness of antidepressants in elderly depressed outpatients; a prospective case series study. *J Clin Psychiatry.* 60: 690-97 (1999).

Knowles SR, Shapiro LE, Shear NH: Anticonvulsant hypersensitivity syndrome: incidence, prevention, and management. *Drug Safety* 489-501 (1999).

Shear NH, Landau M, Malkiewicz I, Katz GG, Neuman MG: Ethanol-modulated cytokine production and expression in skin cells exposed to methotrexate. *Skin Pharmacol Appl Skin Physiol.* 12: 64-78 (1999).

Gupta AK, **Shear NH**: The new oral antifungal agents for onychomycosis of the toenails. *J Eur Acad Dermatol Venerol.* 12: 1-13 (1999).

Gupta AK, Katz HI, **Shear NH**: Drug interactions with itraconazole, fluconazole, and terbinafine and their management. *J Am Acad Dermatol.* 41: 237-49 (1999).

Rochon PA, Anderson GM, Tu JV, Gurwitz JH, Clark JP, **Shear NH**, Lau P: Age- and gender-related use of low-dose therapy and evaluate the minimum effective dose. *J Am Geriatr Soc.* 47: 954-9 (1999).

Shapiro LE, **Shear NH**: Drug-drug interactions: How scared should we be? *Can Med Assoc J.* 161: 1266-7 (1999).

Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, **Shear NH**: Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytotoxicity. *Clin Biochem.* 32: 519-536 (1999).

Neuman MG, **Shear NH**, Cameron RG, Katz G, Tiribelli C: Ethanol-induced apoptosis in vitro. *Clin Biochem.* 32: 547-556 (1999).

"T"

Kalow W, Endrenyi L, **Tang B-K**: Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. *Pharmacology* 58: 281-284 (1999).

Kalow W, Özdemir V, **Tang B-K**, Tothfalusi L, Endrenyi L: The science of pharmacological variability: An assay. *Clin Pharmacol Ther.* 66: 445-447 (1999).

de Champlain J, Karas M, Toal CB, Nadeau R, Larochelle P: Effects of antihypertensive therapies on the sympathetic nervous system. *Can J Cardiol.* 15: 8A-14A (1999).

Toal CB, Motro M, Baird MG, Klinke P, Sclarowski S, Zilberman A, Marmor A, Kostuk WJ, Lotan C, Weiss A, Erne P, Palant A, Stolero D, Belanger L, Turpie AG: Effectiveness of Nifedipine GITS (Nifedipine Gastrointestinal Therapeutic System) in Combination with Atenolol in Chronic Stable Angina. *Can J Cardiol.* 15: 1103-1109 (1999).

Tyndale RF, Li Y, Li N-Y, Messina ES, Miksys S, Sellers EM: Regional variation in the metabolism of dextromethorphan to dextrorphan by rat brain CYP2D1. *Drug Metab Dispos.* 27: 924-930 (1999).

Özdemir V, **Tyndale RF**, Reed K, Herrmann N, Sellers EM, Kalow W, Naranjo CA: Paroxetine steady state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. *J Clin Psychopharmacol.* 19: 472-475 (1999).

Tyndale RF, Tomkins DM: Differences in the propensity for alcohol drinking are reflected in subunit- and region-specific GABAA receptor levels. *Addiction Research* 4: 309-316 (1999).

Tyndale RF, Pianezza ML, Sellers EM: A common genetic defect in nicotine metabolism decreases dependence and lowers cigarette consumption. *Nicotine Tobacco Res* 1: S63-S67 (1999).

Sellers EM, Romach MK, **Tyndale RF**: Pharmacogenetic basis of variation in drug dependence. In: Tucker GT, ed. *Excerpta Medica International Congress Series. Volume 1178: Variability in Human Drug Response.* Amsterdam: Elsevier Sciences B.V., pp 219 (1999).

"U"

Ju C, **Utrecht JP**: Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. *J Pharmacol Exp Ther.* 288: 51-56 (1999).

Utrecht JP: New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system. *Chem Res Toxicol.* 12: 387-395 (1999).

Goebel C, Vogel C, Wulferink M, Mittmann S, Sachs, B, Schraa S, Abel J, Degen G, **Utrecht J**, Gleichmann E: Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages. *Chem Res Toxicol.* 12: 488-500 (1999).

Guest I, **Utrecht J**: Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix. *Med Hypothesis* 53: 145-151 (1999).

Lai WG, Zahid N, **Utrecht JP**: Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. *J Pharmacol Exp Ther.* 291: 292-299 (1999).

"V"

Watts VJ, Vu MN, Wiens BL, Jovanovic V, **Van Tol HH**, Neve KA: Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors. *Psychopharmacology* 141: 83-92 (1999).

"W, X, Y, Z"

Valente CM, DaSilva JN, **Warsh JJ**, Wilson AA, Houle S.: Imaging of phosphodiesterase-IV enzymes: comparison of [11C]rolipram and [11C]Ro 20-1724 in rats. *Synapse* 31: 41-50 (1999).

Andreopoulos S, Li PP, Siu K-P, **Warsh JJ**: Characterization of α -Immunoreactive ADP-ribosylation proteins in postmortem human brain. *J Neurosci Res.* 56: 407-413 (1999).

Ross BM, Turenne S, Moszczynska A, **Warsh JJ**, Kish SJ: Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. *Brain Res.* 821: 407-413 (1999).

Hudson C, Gotowiec A, Seeman M, **Warsh JJ**, Ross, BM: Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. *Biol Psychiatry* 46: 401-405 (1999).

Fields A, Li PP, **Warsh JJ**: Increased cAMP-dependent protein kinase activity in postmortem temporal cortex in bipolar affective disorder patients. *J Neurochem.* 73: 1704-1710 (1999).

Reiach JS, Li, PP, **Warsh JJ**, Kish, SJ, Young LT: Reduced adenylyl cyclase immunolabeling, expression and activity in postmortem temporal cortex of depressed suicide subjects. *J Affective Disorders* 56: 141-151 (1999).

Winn LM, **Wells PG**: Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. *Free Radical Biol Med* 26: 266-274 (1999).

Parman T, Wiley MJ, **Wells PG**: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. *Nature Medicine* 5: 582-585 (1999).